TIL Announces Termination of AXN-2510 Clinical Program—All Rights Revert to ImmuneOnco
Market Chameleon (Wed, 7-Jan 11:58 AM)
Instil Bio Shifts Focus as Subsidiary Halts AXN-2510 Clinical Development and Ends ImmuneOnco Partnership
Market Chameleon (Tue, 6-Jan 8:13 AM)
